LAVAL, QC, March 21 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that James R. Howard-Tripp, President and Chief Executive Officer of
the Company, will present at the Scotia Capital Spring Growth Conference on
Thursday, March 29, 2007 at 11:10 a.m. ET.
Interested parties may access the live webcast by visiting the "Latest
Webcasts" section of the homepage at www.labopharm.com. Please connect at
least 15 minutes prior to the presentation to ensure adequate time for any
software download that may be required to join the webcast. An audio archive
of the presentation will be available for 30 days.
About Labopharm Inc.
Labopharm Inc. is an international specialty pharmaceutical company
focused on the development of drugs incorporating the Company's proprietary
advanced controlled-release technologies. The Company's lead product, a
once-daily formulation of the analgesic tramadol, has been approved and
launched in Europe and is currently under review for approval by the U.S. Food
and Drug Administration. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of
factors, including the uncertainties related to the regulatory process and the
commercialization of the Corporation's products thereafter, if they are
approved. Investors should consult the Corporation's ongoing quarterly filings
and annual reports for additional information on risks and uncertainties
relating to these forward-looking statements. The reader is cautioned not to
rely on these forward-looking statements. The Corporation disclaims any
obligation to update these forward-looking statements.
For further information:
For further information: At Labopharm: Mark D'Souza, Chief Financial
Officer, Tel: (450) 686-0207; At The Equicom Group: Jason Hogan, Media and
Investor Relations, Tel: (416) 815-0700, email@example.com; French: Eric
Bouchard, Tel: (514) 844-7997, firstname.lastname@example.org